Navigation

Archive | Uncategorized

A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults

January 10, 2021

Authors James D Morse (1), L Ignacio Cortinez (2), Brian J Anderson (3)
Affiliations 1 Department of Pharmacology & Clinical Pharmacology, University of Auckland, Park Road, Auckland 023, New Zealand. 2 Department of Anesthesiology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago de Chile 8331150, Chile. 3 Department of Anaesthesiology, University of Auckland, Park Road, Auckland 1023, New Zealand.
Presentation type Poster
Presenters James Morse

Attachments

A universal pharmacokinetic model was developed from pooled paediatric and adult data (40.6 postmenstrual weeks, 70.8 years, 3.1-152 kg). A three-compartment pharmacokinetic model with first-order elimination was superior to a two-compartment model to describe these pooled dexmedetomidine data. Population parameter estimates (population parameter variability %) were clearance (CL) 0.9 L/min/70 kg (36); intercompartmental clearances (Q2) […]

Continue Reading

Modeling of The Relationship Between Ustekinumab Exposure, Fecal Calprotectin and Endoscopic Outcomes in Patients with Crohn’s Disease

January 10, 2021

Authors Zhigang Wang (1), Bram Verstockt (2,3), João Sabino (2,3), Séverine Vermeire (2,3), Marc Ferrante (2,3), Paul Declerck (1), Erwin Dreesen (1,4)
Affiliations 1. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium 2. Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium 3. Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium 4. Department of Pharmacy, Uppsala University, Uppsala, Sweden
Presentation type Oral
Presenters Zhigang Wang

Attachments




Background: Ustekinumab is approved for the treatment of patients with moderate-to-severe Crohn’s disease (CD) and ulcerative colitis. In the UNITI endoscopy sub-study, only 17.4% of patients on ustekinumab achieved endoscopic response and 10.9% of patients achieved endoscopic remission at week 44 (w44).1 Aims: We aimed to investigate if improved endoscopic outcomes could be achieved through dose optimization […]

Continue Reading

External Evaluation of Vancomycin Models

January 10, 2021

Authors Guangda Ma (1), Eamon Duffy (1, 2), Jacqui Hannam (1), Nick Holford (1)
Affiliations (1) The University of Auckland, (2) Auckland District Health Board
Presentation type Poster
Presenters Guangda Ma

Attachments

Introduction Current clinical evidence supports area under the concentration-time curve (AUC) rather than trough concentrations as a more rational target for vancomycin therapy (1). In mid-2019 practice at Auckland District Health Board Hospitals transitioned from trough concentration to AUC guided dosing supported by Bayesian forecasting using the GAVamycin model implemented in NextDose (www.nextdose.org). To support […]

Continue Reading